Use of diabetes drug rosiglitazone is associated with an increased risk for heart attack, a new study has found.
Rosiglitazone was approved in 1999 to treat hyperglycemia (high blood glucose levels) among patients with type 2 diabetes. Concerns about the cardiovascular safety of rosiglitazone first arose in 2007, when a meta-analysis demonstrated a significantly increased risk for myocardial infarction (heart attack) and a borderline significant increase for cardiovascular death.
Type 2 Diabetes
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.
Advertisement
No large, definitive cardiovascular outcomes trials have been conducted with rosiglitazone. However, as a consequence of a 2004 court settlement in New York, GSK was required to post clinical trial results on a public web site.
In the combined studies, rosiglitazone therapy was associated with a significantly increased risk of myocardial infarction by an estimated 28 percent to 39 percent, although the risk of cardiovascular death was not increased.
![Gestational diabetes]( "Gestational diabetes")
The condition is not caused by a lack of insulin, but by the action of hormones produced during pregnancy that blocks the action of insulin.
"An alternative analysis that included trials with no cardiovascular events found a similar hazard. Subgroups classified by study duration and comparator drug also showed elevated odds ratio estimates," the authors said.
"These findings are consistent with prior meta-analyses conducted by GSK, the FDA and most independent investigators demonstrating an increased risk of myocardial infarction in patients treated with rosiglitazone.
"The FDA has announced that it will conduct an advisory committee meeting in July 2010 to consider whether to remove rosiglitazone from the market," they added.
The mechanisms by which rosiglitazone may cause cardiovascular harm are not clear, the authors note, but could involve increases in low-density lipoprotein (LDL, or "bad" cholesterol) levels or genetic effects associated with the production of an enzyme linked to plaque rupture.
The study appears in the July 26 print issue of Archives of Internal Medicine.
Source: ANI
Gestational diabetes
The condition is not caused by a lack of insulin, but by the action of hormones produced during pregnancy that blocks the action of insulin.
Advertisement
"An alternative analysis that included trials with no cardiovascular events found a similar hazard. Subgroups classified by study duration and comparator drug also showed elevated odds ratio estimates," the authors said.
"These findings are consistent with prior meta-analyses conducted by GSK, the FDA and most independent investigators demonstrating an increased risk of myocardial infarction in patients treated with rosiglitazone.
"The FDA has announced that it will conduct an advisory committee meeting in July 2010 to consider whether to remove rosiglitazone from the market," they added.
The mechanisms by which rosiglitazone may cause cardiovascular harm are not clear, the authors note, but could involve increases in low-density lipoprotein (LDL, or "bad" cholesterol) levels or genetic effects associated with the production of an enzyme linked to plaque rupture.
The study appears in the July 26 print issue of Archives of Internal Medicine.
Source: ANI
Diabetes
A comprehensive article on diabetes - both Type 1 and Type 2 diabetes, including : causes, signs, symptoms, diagnosis, treatment, facts and a glossary on diabetes.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.